loading...| Preferred Name |
P-p68 Inhibitor RX-5902 |
| ID |
http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113293 |
| CAS_Registry |
888478-45-3 |
| code |
C113293 |
| Concept_In_Subset |
http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116977 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157712 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C177537 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157711 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C63923 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C176424 |
| Contributing_Source |
CTRP GDC FDA |
| DEFINITION |
An orally bioavailable small molecule inhibitor of phosphorylated-p68 RNA helicase (P-p68), with potential anti-proliferative and antineoplastic activity. Upon oral administration, P-p68 inhibitor RX-5902 may both inhibit the activity of the anti-apoptotic B-cell lymphoma 2 (Bcl-2) protein and facilitate the induction of cyclin-dependent kinase inhibitor 1 (p21). This may prevent G2/M cell cycle progression and lead to growth inhibition in tumor cells. P-p68 is overexpressed in various types of solid tumors but absent in normal tissues, and plays a role in tumor progression and metastasis. p21 is a potent cyclin-dependent kinase inhibitor which regulates cell cycle progression and mediates both growth arrest and cellular senescence. |
| Display_Name |
P-p68 Inhibitor RX-5902 |
| FDA_UNII_Code |
ZU8OM8V5WF |
| FULL_SYN |
Supinoxin P-p68 Inhibitor RX-5902 RX-5902 SUPINOXIN |
| Is_Value_For_GDC_Property | |
| label |
P-p68 Inhibitor RX-5902 |
| Maps_To |
P-p68 Inhibitor RX-5902 |
| NCI_Drug_Dictionary_ID |
755944 |
| PDQ_Closed_Trial_Search_ID |
755944 |
| PDQ_Open_Trial_Search_ID |
755944 |
| Preferred_Name |
P-p68 Inhibitor RX-5902 |
| prefixIRI |
Thesaurus:C113293 |
| prefLabel |
P-p68 Inhibitor RX-5902 |
| Semantic_Type |
Pharmacologic Substance |
| UMLS_CUI |
C3827081 |
| subClassOf |
| Delete | Mapping To | Ontology | Source |
|---|---|---|---|
| There are currently no mappings for this class. | |||